Nanox reports 37% revenue rise but takes $40.7m impairment charge
Nano-X Imaging (NASDAQ: NNOX) posted second-quarter 2026 revenues of $4.2 million, up 37% from $3.0 million in the same period a year earlier, but the headline figure was overshadowed by a $40.7 million impairment charge against the intangible assets tied to its AI solutions business unit. The write-down pushed the company's GAAP net loss to $55.5 million for the quarter, compared with $14.7 million in Q2 2025.
The revenue growth was driven largely by the consolidation of Nanox Health IT, formerly Vaso Healthcare IT, which the company acquired in November 2025 and contributed $0.9 million to the quarter. Teleradiology services accounted for $3.0 million of total revenue, AI and software solutions added $1.0 million, and imaging system and OEM sales contributed $0.2 million.
Impairment and balance sheet pressure
The impairment was triggered by a significant decline in the company's share price alongside reduced revenue and operating forecasts. After the write-down, the fair value of the AI solutions unit's intangible assets stands at $1.9 million. Nanox stressed that the charge carried no cash outflow and did not affect liquidity, and excluded it from its adjusted EBITDA calculation. On that non-GAAP basis, the adjusted EBITDA loss was $11.3 million, modestly wider than the $10.4 million recorded a year earlier.
Cash and equivalents stood at $31.4 million as at 30 June 2026, down from $60.0 million at the end of 2025, reflecting ongoing operating cash consumption of $25.5 million in the first half. Post-quarter, the company raised $8.5 million in gross proceeds through a registered-direct offering and its at-the-market programme, and signalled it intends to continue tapping capital markets.
Legal risk adds a further layer of uncertainty. A securities class action filed in the US District Court of New Jersey in June 2026, captioned Steele v. Nano-X Imaging Ltd., alleges violations of federal securities law relating to disclosures about the company's Korean manufacturing facility. Three shareholders have filed motions to serve as lead plaintiff; Nanox said it cannot yet estimate the financial exposure.
Commercialisation and restructuring
Acting chairman and chief executive Erez Meltzer pointed to concrete operational progress. The company has expanded its US distribution footprint to ten partners, launched the first Nanox Imaging Network site in Philadelphia with live patient scans, and begun receiving reimbursement from insurers. Nanox.AI secured an exclusive reseller agreement with UK-based Vertec Scientific and initiated five new pilot programmes. The company is also pursuing what it described as a potential new CMS reimbursement pathway, which could broaden adoption of its scanning network if successful.
On the cost side, Nanox is restructuring its South Korean operations, transitioning chip manufacturing to third-party partners and cutting the local workforce by 67%. The restructuring is expected to cost approximately $0.9 million and generate annual savings of around $2 million from 2027.
The broader medical imaging AI market is competitive and increasingly crowded, with established players such as Siemens Healthineers, GE HealthCare, and a growing number of software-focused entrants offering AI-assisted radiology tools. Nanox's differentiated position rests on its proprietary digital X-ray source technology and its integrated scan-to-report model, but the impairment of the AI unit's intangibles raises questions about the durability of that positioning. Investors will focus on the pace of NIN site rollouts, reimbursement rate confirmation, and whether the CMS pathway ambitions translate into a formal coverage determination in the near term.